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Abstract
Background: Women with rheumatoid arthritis (RA) have increased morbidity and mortality due
to coronary heart disease. Chronic systemic inflammation is known to accelerate atherosclerosis
and increase arterial stiffness in patients, but other mechanisms may also be involved. Biomarkers
of oxidant stress, inflammation, insulinaemia and endothelial dysfunction were measured in blood
and urine from 46 RA patients and 48 age-matched controls. Plaque formation and intima-medial
thickness (IMT) were measured using B-mode carotid Doppler scan.
Findings: The prevalence of plaque was increased (p = 0.042) in RA patients between 50–59 years
old compared to the same age group in controls. 8-isoprostane (p = 0.004), C-reactive protein (p
< 0.001), interleukin-6 (p < 0.001), insulin (p = 0.035), adiponectin (p = 0.012), vascular cell
adhesion molecule (VCAM) (p = 0.029) and E-selectin (p < 0.001) were all increased while selenium
(p = 0.003) and LDL-cholesterol (p = 0.025) were both decreased in all RA patients. 8-isoprostane
correlated with 10 year cardiac risk (r = 0.55, p < 0.001), VCAM with IMT (r = 0.37, p = 0.012)
and E-selectin with rheumatoid factor titre (r = 0.43, p = 0.003) in RA patients. In the control group,
age, carotid IMT, VCAM, systolic blood pressure and smoking status were all associated with
plaque development whereas in RA patients only age was associated with plaque.
Conclusion: The burden of atherosclerosis is particularly increased in middle-aged women with
RA. Patients with RA have increased levels of oxidant stress, inflammation, insulin and soluble
adhesion molecules. As the association between classical risk factors was much weaker in RA
patients compared to controls, these additional factors may be more important in the accelerated
development of atheroma in RA.
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Findings
Recent studies [1,2] have established that patients with
rheumatoid arthritis (RA) have a 2-fold higher risk of
myocardial infarction than the general population and, in
those with RA for 10 years or more, the risk is increased to
> 3-fold. The mechanisms behind this higher incidence of
coronary heart disease in RA patients are not fully under-
stood but may be related to vascular inflammation and
vascular endothelial injury which is common in RA
patients [3]. Newly diagnosed RA patients have signifi-
cantly impaired endothelial function which can be
improved with anti-inflammatory therapies [4]. Oxidant
stress and the production of intracellular reactive oxygen
species (ROS) have been implicated in the pathogenesis
of a variety of cardiovascular diseases [5]. In synovial fluid
in the inflamed rheumatoid joint, activated neutrophils
produce large amounts of ROS and activated poly-mor-
phonuclear cells are also likely to increase oxidant stress
[6]. Hyperinsulinaemia is associated with increased long-
term mortality following acute myocardial infarction in
non-diabetic patients [7]; in vitro studies show that insu-
lin has both atherogenic (in supraphysiological concen-
trations) and anti-atherogenic (in physiological
concentrations) effects on the vessels. The latter vasodila-
tory action might be lost or down-regulated in the insulin
resistant state, where increased insulin secretion in combi-
nation with hyperglycaemia leads to smooth muscle cell
hypertrophy and hyperplasia, and excess synthesis of
extra-cellular matrix proteins. Adiponectin, an adipose-
specific secretory protein, has been implicated in insulin-
resistance and development of atherosclerosis in obese
and diabetic individuals; it has also been suggested that
adiponectin has anti-inflammatory effects on the vascular
wall [8]. Adhesion molecules are transmembrane glyco-
proteins that facilitate the recruitment of leucocytes to
sites of inflammation including developing atheroscle-
rotic lesions and circulating concentrations may be useful
predictors of cardiovascular disease [9]. 
The present study was designed to examine the extent of
oxidant stress, inflammation and hyperinsulinaemia in
patients with RA and whether these factors may contribute
to atherogenesis in this population. We also sought to
determine the potential relationship between other, more
classic, risk factors for atherosclerosis and subclinical
atherosclerosis in RA.
Methods
The study was approved by the Central Manchester Local
Research Ethics Committee and all subjects gave written
informed consent. We recruited 46 female RA patients
and 48 age-matched female controls. Blood and urine
samples were taken following an overnight fast and avoid-
ance of alcohol for 48 hours. A detailed clinical history
including family history of ischemic heart disease (FH of
IHD) and current medications was taken. The 10-year risk
of myocardial infarction was calculated. Examination
included basic anthropomorphic measurements, blood
pressure and, in RA patients, assessment of current disease
activity using the 28-joint Disease Activity Score (DAS28).
Carotid Ultrasound was performed by a single operator
using an ATL HDI 5000 scanner equipped with 7-4 MHz
linear array transducer. IMT was reported as previously
described [10]. Ultrasound images were also scored for
plaque in the proximal common, distal common, carotid
bulb, internal and external carotid arteries [11].
8-isoprostane (8-IP), malondialdehyde (MDA), selenium,
total antioxidant capacity in whole and protein-free
serum, vitamin A and vitamin E were assayed as previ-
ously described [12]. C-reactive protein (CRP) was
assayed by sandwich ELISA technique using antibodies
from Dakocytomation (Glostrop, Denmark). IL-6 was
measured using a high-sensitivity ELISA kit (Diaclone,
Besancon, France). Insulin was measured by radio-immu-
noassay [13], insulin sensitivity being calculated as
HOMA-S = 1/(insulin × glucose/22.5). Adiponectin,
VCAM, E-selectin and P- selectin were all measured using
DuoSet® ELISA development systems (R&D Systems, Min-
neapolis, MN).
Total cholesterol, HDL, TG and glucose were all deter-
mined by standard automated techniques and LDL-cho-
lesterol estimated by the Friedewald formula.
Rheumatoid factor was measured by nephelometry.
Statistical Analysis
Values are shown either as medians with interquartile
ranges or as the number of affected individuals with per-
centage of the total. Where appropriate, the Mann-Whit-
ney U test or Fisher's Exact Probability test was used to
calculate significance between groups. Significance of cor-
relations between parameters was assessed by the Spear-
man Rank test. Univariate logistic regression analysis was
conducted on candidate variables in the control and RA
groups using the occurrence of plaque (0 or 1) as the
response.
Results
We studied 46 female RA patients with a median (IQR)
age of 57 (51.5–60) years who had established RA disease
for a median (IQR) of 12 (7–19) years. Of these patients,
33 (72%) were RF positive, 34 (74%) had radiographic
erosions and 19 (41%) had at least one joint replacement.
With regard to treatment, 44 (96%) had been treated with
at least one disease-modifying anti-rheumatic drug
(DMARD), 16 (35%) were currently taking steroids, 12
(26%) were using a non-selective NSAID and 11 (24%)
were on a COX-2 inhibitor. The median (IQR) DAS28BMC Research Notes 2009, 2:83 http://www.biomedcentral.com/1756-0500/2/83
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score was 3.6 (2.4–4.6) indicating moderately active dis-
ease.
Risk factors for controls and RA patients are shown in
Table 1 and, with the exception of calculated LDL-choles-
terol which was lower in RA patients, there was no signif-
icant difference in other classic cardiovascular risk factors
between groups. There was also no difference in the
carotid IMT.
Overall, there was no statistical difference between con-
trols and RA patients with carotid plaque (Table 2). How-
ever, the prevalence of carotid plaque was significantly
increased (p = 0.042) in RA patients aged 50–59 years old.
In the < 50 year old age group, 2/13 patients but no con-
trols had evidence of plaque formation. No difference in
plaque formation was found in the older (> 60 years) age
group.
The results for biomarkers are shown in Table 3 and Figure
1. In the RA group, we found clear evidence for increased
lipid peroxidation as urinary 8-IP levels were significantly
elevated (p = 0.004) compared to controls (Figure 1a).
Plasma MDA, a less sensitive marker of lipid peroxidation,
was unchanged. The total antioxidant capacity (in whole
serum and protein-free serum), vitamin A and vitamin E
levels were no different from control values. Serum sele-
nium levels were significantly reduced (p = 0.003) in RA
(Figure 1b). C-reactive protein (Figure 1c) and IL-6 (Fig-
ure 1d), were both significantly increased (p < 0.001) in
RA. Similarly, insulin (Figure 1e) and adiponectin were
also significantly increased (p = 0.035 and p = 0.012
respectively) while insulin sensitivity was decreased (p =
0.039) in RA patients. Plasma glucose levels were
unchanged. Two of three soluble adhesion molecules,
VCAM and E-selectin (Figure 1f), were increased (p =
0.029 and p < 0.001 respectively) in RA.
Spearman correlations between biomarkers and cardio-
vascular risk factors for controls and RA patients are
shown in Table 4. In the RA group, urinary 8-IP correlated
positively with age and smoking as well as with 10 year
cardiac risk (r = 0.552, p < 0.001), E-selectin (r = 0.422, p
= 0.004), TG (r = 0.392, p = 0.008) and CRP (r = 0.313, p
= 0.034) and negatively with HDL (r = -0.418, p = 0.005).
Serum selenium in RA was associated with HDL (r =
0.388, p = 0.009) and TG (r = -0.317, p = 0.036). As
expected, IL-6 and CRP both correlated with DAS28 (r =
0.639, p < 0.001 and r = 0.316, p = 0.041 respectively).
Insulin correlated positively with BMI, SBP and glucose (r
= 0.314, p = 0.034) and negatively with adiponectin (r = -
0.432, p = 0.003). VCAM was associated with BMI while
E-selectin was associated with BMI, LDL and smoking as
well as RF titre (r = 0.429, p = 0.003). We found that
VCAM was associated with carotid IMT in both patients
and controls. In the patient group, we also found a nega-
tive correlation between IL-6 and IMT.
With regard to association with carotid plaque (Table 5),
univariate logistic regression analysis of the control group
found that plaque was associated with age (p = 0.013),
IMT (p = 0.008), VCAM (p = 0.007), SBP (p = 0.014) and
smoking (p = 0.010). In contrast, in the RA group, only
age (p = 0.034) was significantly associated with plaque.
Discussion
The causes of increased coronary heart disease and cardi-
ovascular mortality in RA patients may be multi-factorial,
Table 1: Cardiovascular risk factors in RA patients and controls.
risk factor Controls RA patients p value
age 57 (51.5–60) 56 (49–60) ns
BMI 25.16 (23.30–28.75) 25.53 (23.39–29.55) ns
waist/hip 0.818 (0.778–0.839) 0.846 (0.800–0.886) ns
SBP 128 (117.5–143) 128 (122–140) ns
DBP 78 (72–84) 80 (73.5–84.5) ns
total cholesterol 5.75 (4.9–6.75) 5.5 (4.5–6.1) ns
HDL-cholesterol 1.55 (1.30–2.03) 1.70 (1.40–2.00) ns
triglycerides 1.20 (0.85–1.50) 1.10 (0.80–1.43) ns
LDL-cholesterol 3.50 (2.73–4.33) 3.09 (2.34–3.78) 0.025
10 year cardiac risk 5.75 (3.20–10.35) 4.90 (1.58–7.93) ns
IMT 0.055 (0.047–0.062) 0.053 (0.047–0.060) ns
smoking 24 (50%) 30 (65%) ns
hypertension 6 (13%) 12 (26%) ns
FH of IHD 11 (23%) 16 (35%) ns
Results are expressed either as median (interquartile range) or as the number of affected individuals (percentage of the total). Data were analysed 
using the Mann-Whitney U-test (continuous variables) or Fisher's Exact Probability test (dichotomous variables). ns = not significant. Units were 
expressed as follows: age as years; SBP and DBP as mmHg; total cholesterol, HDL-cholesterol, triglycerides and LDL-cholesterol as mmol/l; 10 year 
cardiac risk as %; IMT as cm.BMC Research Notes 2009, 2:83 http://www.biomedcentral.com/1756-0500/2/83
Page 4 of 7
(page number not for citation purposes)
but cannot be explained merely by conventional risk fac-
tors such as age, gender, hyperlipidaemia, hypertension,
smoking or excess weight [14].
It is still a matter of debate [5] whether the increased oxi-
dant stress present in cardiovascular disease has a primary
causative role or is rather a vascular sequel of disease pro-
gression. In the atherosclerotic process, lipids are the first
line of radical attack and raised levels of 8-IP have been
found in both serum and synovial fluid from patients
with different rheumatic diseases including a small
number with RA [15]. We have shown increased urinary
8-IP levels in RA patients, the median level being 40%
greater than control. In addition, urinary 8-IP had a strong
and significant association with 10 year cardiac risk in our
RA group. Elevated levels of MDA, a product of polyunsat-
urated fat oxidation, have been reported in the serum and
synovial fluid of patients with RA [6] but we found no dif-
ference in plasma MDA levels between groups. Selenium
was the only measure of antioxidant capacity that showed
a significant reduction in our RA group in agreement with
an earlier finding [16]. Long-term selenium supplementa-
tion in RA patients restored selenium and glutathione per-
oxidase levels in serum and red blood cells, but failed to
improve glutathione peroxidase levels in granulocytes
[17].
Table 2: Frequency of Carotid Plaque with Age in RA patients 
and controls.
age (years) controls RA patients p value
< 50 0/8 (0%) 2/13 (15%) ns
50–59 6/26 (23%) 10/19 (53%) 0.042
> 60 8/14 (57%) 7/14 (50%) ns
all subjects 14/48 (29%) 19/46 (41%) ns
Values are shown as the number of affected individuals with 
percentage of the total. Fisher's Exact Probability test was used to 
calculate significance between groups.
ns = not significant.
Key markers of lipid peroxidation, antioxidant status, inflammation, insulinaemia and endothelial dysfunction in control and RA  groups Figure 1
Key markers of lipid peroxidation, antioxidant status, inflammation, insulinaemia and endothelial dysfunction 
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Pro-inflammatory cytokines are involved in the develop-
ment of RA and mediate synovial inflammation in the
rheumatoid joint. Elevated IL-6 levels have been found in
synovial fluid and serum in RA patients [18] and serum
IL-6 levels correlated with disease activity and radio-
graphic joint damage [19]. CRP is produced in the liver in
response to IL-6 and, in addition to its role as a marker of
disease activity in RA, CRP has also been shown to be
associated with carotid plaque in RA [20]. As anticipated,
both IL-6 and CRP levels were increased in our patient
group and correlated with the DAS28; however, neither
marker was associated with plaque. Of course, it should
also be borne in mind that plaque formation is the result
of exposure to a range of known and unknown risk factors
over the whole of a patient's lifetime.
Non-diabetic patients with hyperinsulinaemia tend to be
more obese and suffer more frequently from hypertension
and myocardial infarction [7]. Insulin was elevated and
HOMA-S decreased in our RA patients, but glucose levels
were no different from controls. Serum adiponectin was
also increased in our RA patients. Adiponectin is known
to suppress the expression of adhesion molecules in vas-
cular endothelial cells and cytokine production from mac-
rophages, thus inhibiting the inflammatory processes that
occur during the early phases of atherosclerosis. Increased
adiponectin levels in RA may therefore be in part an
attempt to suppress a profound inflammatory insult [21].
The decrease in total LDL-cholesterol in our RA group may
imply protection from atheroscelerosis. It has been shown
[22] that individuals with higher adiponectin levels had
lower LDL-cholesterol levels and that, when adiponectin
was raised, insulin resistance was low and the lipid profile
good.
Table 3: Biomarkers of lipid peroxidation, antioxidant status, 
inflammation, insulinaemia and endothelial dysfunction in RA 
patients and controls.
marker controls RA patients p value
8-IP 0.659 (0.449–0.845) 0.925 (0.598–1.248) 0.004
MDA 3.195 (2.825–3.434) 2.900 (2.648–3.346) ns
selenium 91.14 (84.12–101.3) 84.55 (77.18–91.08) 0.003
TAC (ws) 730.0 (586.9–888.0) 728.2 (532.5–905.9) ns
TAC (pfs) 343.7 (292.2–394.9) 334.7 (262.9–426.0) ns
vitamin A 2.714 (2.472–3.191) 2.615 (2.241–3.224) ns
vitamin E 13.63 (11.91–16.53) 13.41 (12.40–15.27) ns
CRP 3.025 (1.269–5.246) 9.335 (5.201–11.79) < 0.001
IL-6 0.046 (0–0.398) 3.723 (1.773–11.25) < 0.001
insulin 6.65 (4.4–8.9) 7.65 (5.9–11.4) 0.035
glucose 4.700 (4.5–5.0) 4.700 (4.4–5.1) ns
HOMA-S 0.718 (0.54–1.08) 0.615 (0.40–0.80) 0.039
adiponectin 3.369 (2.31–4.74) 4.543 (3.15–6.97) 0.012
VCAM 241.1 (200.4–260.8) 253.8 (224.7–298.0) 0.029
E-selectin 86.74 (54.19–107.3) 113.4 (86.74–113.4) < 0.001
P-selectin 17.34 (14.49–23.62) 20.29 (16.47–25.40) ns
Results are expressed as median (interquartile range). The Mann-
Whitney U test was used to calculate significance between groups. ns 
= not significant. Units were expressed as follows: 8-IP as ng/g 
creatinine; MDA and vitamin A as μmol/l; selenium, VCAM, E-selectin 
and P-selectin as μg/l; TAC (ws and pfs) as mmol/l trolox equivalents; 
vitamin E, CRP and adiponectin as mg/l; IL-6 as ng/l; insulin as mU/l; 
glucose as mmol/l.
Table 4: Spearman correlations between biomarkers and potential cardiovascular risk factors.
cardiovascular risk factor
biomarker age BMI LDL IMT SBP smoking
controls:
8-IP 0.090 0.272 0.039 0.131 0.161 0.416**
selenium 0.299* -0.305* 0.227 -0.031 -0.240 -0.281
CRP 0.059 0.427** 0.238 0.205 0.255 0.043
IL-6 0.091 0.421** 0.018 0.201 0.248 0.214
insulin 0.009 0.408** 0.148 0.125 -0.030 0.014
adiponectin 0.142 -0.256 0.015 0.065 0.132 0.281
VCAM 0.413** 0.062 0.327* 0.339* 0.191 0.232
E-selectin 0.212 0.111 0.434** 0.257 0.252 0.188
RA patients:
8-IP 0.321* 0.198 0.271 0.170 0.088 0.308*
selenium 0.160 0.100 0.189 0.073 0.191 0.117
CRP 0.221 0.160 0.019 0.184 0.215 0.257
IL-6 -0.185 -0.251 -0.234 -0.342* -0.242 0.049
insulin 0.245 0.594** 0.119 0.254 0.369* 0.117
adiponectin 0.265 -0.331* -0.049 0.067 0.127 -0.031
VCAM 0.102 0.297* 0.214 0.369* 0.188 0.019
E-selectin 0.015 0.389** 0.388** 0.198 0.135 0.372*
Results are expressed as r values. * p < 0.05; ** p < 0.01.BMC Research Notes 2009, 2:83 http://www.biomedcentral.com/1756-0500/2/83
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We found that two biomarkers of endothelial activation,
E-selectin and VCAM, were raised in RA patients support-
ing the notion that patients with vascular changes may be
most prone to atherosclerotic complications. VCAM is
associated with IMT in patients and controls; E-selectin
with RF titre in our patients. In the Norfolk Arthritis Reg-
istry, Goodson [14] noted that the risk of cardiovascular
death was increased in patients with rheumatoid factor.
Carotid plaque develops earlier in our RA group, the
incidence being significantly higher in patients between
50–59 years than in the same control age group. In pre-
vious studies [23,24], carotid plaques tended to have a
higher frequency in RA patients without reaching statis-
tical significance. The intima-media thickness of the
common carotid artery measured by ultrasound imaging
has been shown to be a reliable marker of preclinical
atherosclerosis [25], but no difference was found
between our groups. However, the great majority of our
patients had been treated with DMARDs and methotrex-
ate, for example, is known to decrease IMT [26]. Univar-
iate logistic regression analysis showed that only age
independently predicted plaque formation in the RA
group. Plaque rupture is now acknowledged as the major
cause of unstable angina, myocardial infarction and sud-
den cardiac death; strategies to reduce this risk include
inhibition of inflammatory cytokines and the use of
antioxidants [27]. We conclude that the increase in oxi-
dant stress, inflammation, insulin resistance and adhe-
sion molecules demonstrated in our RA patients could
all exert additive atherogenic effects.
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